RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation

Leukemia

Volumn 23, Issue 8, 2009, Pages 1426-1431

  Kuo, M C ^a   Liang, D C ^b   Huang, C F ^a   Shih, Y S ^b   Wu, J H ^a   Lin, T L ^a   Shih, L Y ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; RAS PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CHROMOSOME DUPLICATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MONOSOMY 7; NONSENSE MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILENT GENE; TRISOMY 13; TRISOMY 21;

EID: 68749109365     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.48     Document Type: Article

References (32)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors: Pathology & Genetics Tumors of Haematopoietic and lymphoid tissues. IARC Press: Lyon, 2001, pp 45-52.
3. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up. Leukemia 1998; 12: 887-892.
4. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 1990; 76: 1214-1219.
5. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16: 1207-1212.
6. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 466-475.
7. Shih LY, Lin TL, Wang PN, Wu JH, Dunn P, Kuo MC et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer 2004; 101: 989-998.
8. Shih LY, Huang CF, Lin TL, Wu JH, Wang PN, Dunn P et al. Heterogeneous patterns of CEBPα mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myeloid leukemia. Clin Cancer Res 2005; 11: 1821-1826.
9. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84 321-330.
10. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93: 3444-3449.
11. Asou N. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 2003; 45: 129-150.
12. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502-513.
13. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999; 93: 1817-1824.
14. Roumier C, Eclache V, Imbert M, Davi F, MacIntyre E, Garand R et al M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: A report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2003; 101: 1277-1283.
15. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101: 673-680.
16. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004; 104: 1474-1481.
17. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316-2324.
18. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74: 47-53.
19. Nakao M, Horiike S, Fukushima-Nakase Y, Nishimura M, Fujita Y, Taniwaki M et al. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/ runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br J Haematol 2004; 125 709-719.
20. Osato M. Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 2004; 23: 4284-4296.
21. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
22. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
23. Hopfner KP, Eichinger A, Engh RA, Laue F, Ankenbauer W, Huber R et al Crystal structure of a thermostable type B DNA polymerase from Thermococcus gorgonarius. Proc Natl Acad Sci USA 1999; 96: 3600-3605.
24. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175.
25. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K et al Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 2000; 96: 3154-3160.
26. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308-1316.
27. Imai O, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S et al. Mutational analyses of the AML1 gene in patients with myelodysplastic syndrome. Leuk Lymphoma 2002; 43: 617-621.
28. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 2002; 99: 1364-1372.
29. Harada H, Harada Y. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Crit Rev Eukartyot Gene Expr 2005; 15: 183-196.
30. Kanno T, Kanno Y, Chen LF, Ogawa E, Kim WY, Ito Y. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol 1998; 18: 2444-2454.
31. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179-198.
32. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 2000; 96: 2862-2869.